Immunotherapy for the treatment of colorectal cancer.
J Surg Oncol
; 123(3): 760-774, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-33595891
Immune checkpoint inhibition (ICI) has transformed the management of metastatic colorectal cancer (mCRC) with mismatch-repair deficiency (dMMR) and microsatellite instability (MSI-H), though this constitutes on average less than 5% of mCRC, and ICI is ineffective in preserved MMR/microsatellite stable disease (pMMR/MSS). Here we review the efficacy of ICI in dMMR/MSI-H mCRC, poor response to ICI in pMMR/MSS mCRC, role for ICI in locally advanced disease, biomarkers of response, novel immunotherapies, and future directions in targeting resistance mechanisms.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Inibidores de Checkpoint Imunológico
/
Imunoterapia
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
J Surg Oncol
Ano de publicação:
2021
Tipo de documento:
Article